What is Sutro Biopharma's impairment charges?

Sutro Biopharma (STRO) reported impairment charges of $423.5K in Q4 2025.

What does impairment charges mean?

Non-cash asset impairment charges added back in the operating cash flow reconciliation since they don't represent cash outflows.

Sutro Biopharma STRO Impairment Charges

Impairment Charges at other companies

XencorXNCR

$0-100%

Other financials

Income statement

See full

Revenue$14.5M-16.5%

Operating income-$29.7M+56.7%

Net income-$38.5M+49.3%

EPS (diluted)-$2.94+67.6%

Balance sheet

See full

Cash & equivalents$73.7M-30.6%

Total debt$13.6M-36.3%

Total equity-$66.9M-159%

Total assets$242.0M-24.7%

Cash flow

See full

Operating cash flow-$42.3M+37.7%

CapEx--100%

Free cash flow-$42.3M+37.8%

Valuation

See full

Market cap$489.66M+624%

Enterprise value$429.61M-2,600%

P/S4.9×+3.9×

Profitability

See full

Operating margin-120%-48.6pp

Net margin-154.2%-56.7pp

FCF margin-152.2%-51.1pp

Returns & leverage

See full

Return on equity-234.2%—

Debt / equity0.5×+0.3×

Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:AssetImpairmentCharges.

The official record: Sutro Biopharma’s 10-K, filed March 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's impairment charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sutro Biopharma's impairment charges?: Sutro Biopharma (STRO) reported impairment charges of $423.5K in Q4 2025.
What does impairment charges mean?: Non-cash asset impairment charges added back in the operating cash flow reconciliation since they don't represent cash outflows.